[go: up one dir, main page]

PE20121088A1 - Nuevos compuestos eficaces como inhibidores de la xantina-oxidasa, metodo para la preparacion de los mismos y composicion farmaceutica que los contiene - Google Patents

Nuevos compuestos eficaces como inhibidores de la xantina-oxidasa, metodo para la preparacion de los mismos y composicion farmaceutica que los contiene

Info

Publication number
PE20121088A1
PE20121088A1 PE2012000438A PE2012000438A PE20121088A1 PE 20121088 A1 PE20121088 A1 PE 20121088A1 PE 2012000438 A PE2012000438 A PE 2012000438A PE 2012000438 A PE2012000438 A PE 2012000438A PE 20121088 A1 PE20121088 A1 PE 20121088A1
Authority
PE
Peru
Prior art keywords
halogen
xanthine
oxidase
inhibitors
pharmaceutical composition
Prior art date
Application number
PE2012000438A
Other languages
English (en)
Inventor
Tae Hun Kim
Jeong Uk Song
Geun Tae Kim
Sung Pil Choi
Cheol Kyu Jung
Deok Seong Park
Eun Sil Choi
Hyun Jung Park
Heui Sul Park
Ki Chul Koo
Wan Su Park
Vasily Artemov
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43857261&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20121088(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of PE20121088A1 publication Critical patent/PE20121088A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE INDOL DE FORMULA (1) DONDE A ES (A-i), (A-ii), (A-iii), ENTRE OTROS, EN DONDE J ES H, HALOGENO O HALOGENO-ALQUILO(C1-C6); X ES O O S; D ES H, HALOGENO, CN, NITRO, ENTRE OTROS; E ES H, CN, HALOGENO, ALCOXI(C1-C6), ENTRE OTROS; G ES H O ALQUILO OPCIONALMENTE SUSTITUIDO; Q ES H, ALQUILO OPCIONALMENTE SUSTITUIDO, ENTRE OTROS; Y ES H, HALOGENO, ALQUILO OPCIONALMENTE SUSTITUIDO, ALCOXI(C1-C6), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: ACIDO 1-(3-CIANO-1-ISOPROPIL-INDOL-5-IL)PIRAZOL-4-CARBOXILICO; ACIDO 1-[3-CIANO-1-(1-FLUOROPROPAN-2-IL)-INDOL-5-IL]-PIRAZOL-4-CARBOXILICO; ACIDO 2-[3-CIANO-1-(2-METOXIETIL)-INDOL-5-IL]ISONICOTINICO; ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA XANTINA-OXIDASA SIENDO UTILES EN EL TRATAMIENTO DE HIPERURICEMIA, GOTA, INSUFICIENCIA CARDIACA, HIPERTENSION
PE2012000438A 2009-10-07 2010-10-04 Nuevos compuestos eficaces como inhibidores de la xantina-oxidasa, metodo para la preparacion de los mismos y composicion farmaceutica que los contiene PE20121088A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20090095363 2009-10-07

Publications (1)

Publication Number Publication Date
PE20121088A1 true PE20121088A1 (es) 2012-08-17

Family

ID=43857261

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000438A PE20121088A1 (es) 2009-10-07 2010-10-04 Nuevos compuestos eficaces como inhibidores de la xantina-oxidasa, metodo para la preparacion de los mismos y composicion farmaceutica que los contiene

Country Status (27)

Country Link
US (1) US8729273B2 (es)
EP (1) EP2467378B1 (es)
JP (1) JP5702392B2 (es)
KR (1) KR101751325B1 (es)
CN (1) CN102574839B (es)
AP (1) AP3346A (es)
AR (1) AR078504A1 (es)
AU (1) AU2010304091B2 (es)
BR (1) BR112012007828B8 (es)
CA (1) CA2774133C (es)
CL (1) CL2012000738A1 (es)
CO (1) CO6430501A2 (es)
EA (1) EA021025B1 (es)
EC (1) ECSP12011793A (es)
ES (1) ES2599829T3 (es)
HK (1) HK1170224A1 (es)
IL (1) IL218669A (es)
MA (1) MA33880B1 (es)
MX (1) MX2012003782A (es)
MY (1) MY162813A (es)
PE (1) PE20121088A1 (es)
SG (1) SG179186A1 (es)
TR (1) TR201203989T1 (es)
TW (1) TWI423962B (es)
UA (1) UA110197C2 (es)
WO (1) WO2011043568A2 (es)
ZA (1) ZA201202544B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI548630B (zh) * 2011-04-06 2016-09-11 Ｌｇ生命科學有限公司 １－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸結晶型及其製造方法
SG2014012926A (en) * 2011-08-30 2014-06-27 Chdi Foundation Inc Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
JP6091603B2 (ja) 2013-03-29 2017-03-08 帝人ファーマ株式会社 ピラゾール誘導体
CN114588157A (zh) 2014-07-17 2022-06-07 Chdi基金会股份有限公司 用于治疗hiv相关病症的方法和组合物
CN104774172B (zh) * 2015-04-08 2017-03-22 河南师范大学 一种3‑氰基吲哚类化合物的合成方法
DK3344604T3 (da) * 2015-09-02 2020-12-07 Sunshine Lake Pharma Co Ltd Carboxy-substituerede (hetero) aromatiske ringderivater og fremstillingsfremgangsmåde og anvendelser deraf
CN106008488B (zh) * 2016-05-20 2018-10-30 广东东阳光药业有限公司 氰基吲哚类衍生物及其制备方法和用途
IL266972B2 (en) 2016-12-02 2024-04-01 Bioverativ Therapeutics Inc Methods for the treatment of hemophilic arthritis with the help of chimeric blood coagulation factors
CN110612286A (zh) * 2017-02-28 2019-12-24 广东东阳光药业有限公司 氰基取代的稠合双环衍生物及其制备方法和用途
MX2020012397A (es) 2018-05-18 2021-04-12 Bioverativ Therapeutics Inc Metodos de tratamiento de la hemofilia a.
WO2019231290A1 (ko) * 2018-06-01 2019-12-05 (주) 오토파지사이언스 신규한 화합물 및 이를 포함하는 약학적 조성물
CN111072647B (zh) * 2019-12-11 2021-02-26 沈阳药科大学 3-取代吲哚-5-氧代-4,5-二氢-1,2,4-噁二唑类化合物及其用途
CN111072634B (zh) * 2020-01-03 2022-07-22 中国医科大学 1-取代-3-取代-5-取代酰胺-1h-吲哚类化合物及其制备方法和应用
WO2022098057A1 (ko) 2020-11-04 2022-05-12 주식회사 엘지화학 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산의 결정성 입자의 제조방법 및 이를 포함하는 약학적 조성물
EP4257123A4 (en) * 2020-12-01 2024-05-08 Lg Chem, Ltd. STABLE ORAL FORMULATION CONTAINING 1-(3-CYANO-1-ISOPROPYL-INDOL-5-YL)PYRAZOLE-4-CARBOXYLIC ACID
EP4257124A4 (en) 2020-12-01 2024-05-29 Lg Chem, Ltd. ORAL FORMULATION CONTAINING 1-(3-CYANO-1-ISOPROPYL-INDOL-5-YL)PYRAZOLE-4-CARBOXYLIC ACID AND METHOD FOR THE PREPARATION THEREOF
CN112920170B (zh) * 2021-01-29 2023-06-20 中国医科大学 N-（吲哚-5-基）芳香杂环酰胺类化合物及其制备方法和用途
MX2023011500A (es) * 2021-04-16 2023-10-04 Lg Chemical Ltd Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico.
KR102708080B1 (ko) * 2021-04-27 2024-09-20 주식회사 엘지화학 잔틴 옥시다아제 저해제 합성을 위한 중간체의 제조 방법
WO2022231263A1 (ko) * 2021-04-27 2022-11-03 주식회사 엘지화학 잔틴 옥시다아제 저해제 합성을 위한 중간체의 제조 방법
WO2022231262A1 (ko) * 2021-04-27 2022-11-03 주식회사 엘지화학 잔틴 옥시다아제 저해제의 제조 방법
CA3218011A1 (en) * 2021-04-29 2022-11-10 Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. A xanthine oxidase inhibitor
AU2022292402A1 (en) 2021-06-15 2023-12-14 Lg Chem, Ltd. Pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid
AR126164A1 (es) 2021-06-17 2023-09-27 Lg Chemical Ltd Formulación compuesta para dosificación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico
KR20230006408A (ko) * 2021-07-02 2023-01-10 주식회사 엘지화학 잔틴 옥시다아제 저해제 합성을 위한 중간체의 제조 방법
TWI822151B (zh) * 2021-07-02 2023-11-11 南韓商Ｌｇ化學股份有限公司 製備黃嘌呤氧化酶抑制劑的方法
EP4516788A1 (en) * 2022-04-27 2025-03-05 Atom Therapeutics Co., Ltd Compound capable of being used for gout
WO2023208108A1 (zh) * 2022-04-27 2023-11-02 江苏新元素医药科技有限公司 可用于降尿酸的化合物
CN116283946B (zh) * 2023-03-27 2024-05-07 武汉工程大学 5-(n-取代吲哚-5-基)异噁唑-3-甲酸衍生物及其合成方法和应用
KR20250009377A (ko) 2023-07-10 2025-01-17 주식회사 엘지화학 잔틴 옥시다아제 저해제 합성을 위한 중간체의 제조 방법
CN118598859A (zh) * 2024-05-21 2024-09-06 武汉工程大学 一种含氮杂环吲哚类黄嘌呤氧化酶抑制剂及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100221041B1 (ko) 1990-11-30 1999-09-15 야스이 쇼사꾸 2-아릴티아졸 유도체 및 그의 약제학적 조성물
ID21775A (id) 1996-10-25 1999-07-22 Yoshitomi Pharmaceutical Senyawa-senyawa 1-fenilpirazol dan penggunaan farmasinya
US6635640B2 (en) * 2000-06-30 2003-10-21 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
CA2413044A1 (en) * 2000-07-10 2002-01-17 Bristol-Myers Squibb Company Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives
WO2008011131A2 (en) * 2006-07-21 2008-01-24 Takeda Pharmaceutical Company Limited Amide compounds
DE10163991A1 (de) * 2001-12-24 2003-07-03 Merck Patent Gmbh Pyrrolo-pyrimidine
AU2003249535A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors
KR20080035594A (ko) * 2005-07-01 2008-04-23 닛뽕 케미파 가부시키가이샤 크산틴옥시다아제 저해제
AU2006300422A1 (en) 2005-10-07 2007-04-19 Astellas Pharma Inc. Triarylcarboxylic acid derivative
US8188113B2 (en) * 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
JP2008179621A (ja) * 2006-12-28 2008-08-07 Taisho Pharmaceutical Co Ltd 含窒素飽和複素環化合物
WO2008126770A1 (ja) 2007-04-05 2008-10-23 Astellas Pharma Inc. トリアリールカルボン酸誘導体の製造方法
EP2133331A4 (en) 2007-04-11 2011-06-22 Kissei Pharmaceutical FIVE-GLASS HETEROCYCLIC DERIVATIVE AND ITS USE IN MEDICAL PURPOSES
PL2133332T3 (pl) * 2007-04-11 2014-02-28 Kissei Pharmaceutical Pochodna aza(indolu) i jej zastosowanie do celów medycznych
EP2338887A4 (en) 2008-10-15 2012-05-09 Kissei Pharmaceutical FUSIONED HETEROCYCLIC DERIVATIVE AND ITS USE FOR MEDICAL PURPOSES
CA2740766C (en) 2008-10-16 2016-02-02 Automatic Bar Controls, Inc. Apparatus and method and turntable for on-demand distributing of a food product
JP5529876B2 (ja) * 2008-10-17 2014-06-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｍｍｐ−１３阻害剤として有用なヘテロアリール置換インドール化合物
EP2480529A1 (en) * 2009-09-24 2012-08-01 F. Hoffmann-La Roche AG Indole derivatives as crac modulators

Also Published As

Publication number Publication date
US20120184582A1 (en) 2012-07-19
SG179186A1 (en) 2012-05-30
ECSP12011793A (es) 2012-05-30
TWI423962B (zh) 2014-01-21
ES2599829T3 (es) 2017-02-03
MY162813A (en) 2017-07-31
KR101751325B1 (ko) 2017-06-27
EA201270520A1 (ru) 2012-10-30
US8729273B2 (en) 2014-05-20
CN102574839B (zh) 2015-11-25
WO2011043568A3 (en) 2011-09-29
KR20110037883A (ko) 2011-04-13
AR078504A1 (es) 2011-11-09
WO2011043568A2 (en) 2011-04-14
HK1170224A1 (zh) 2013-02-22
IL218669A (en) 2016-08-31
BR112012007828B8 (pt) 2021-05-25
BR112012007828B1 (pt) 2021-01-12
CN102574839A (zh) 2012-07-11
JP2013507355A (ja) 2013-03-04
CL2012000738A1 (es) 2012-09-14
EA021025B1 (ru) 2015-03-31
AU2010304091A1 (en) 2012-04-19
UA110197C2 (ru) 2015-12-10
TW201118077A (en) 2011-06-01
EP2467378A4 (en) 2013-04-24
CA2774133C (en) 2019-06-25
JP5702392B2 (ja) 2015-04-15
TR201203989T1 (tr) 2012-09-21
ZA201202544B (en) 2012-12-29
AP2012006191A0 (en) 2012-04-30
CA2774133A1 (en) 2011-04-14
CO6430501A2 (es) 2012-04-30
IL218669A0 (en) 2012-05-31
AP3346A (en) 2015-07-31
EP2467378A2 (en) 2012-06-27
EP2467378B1 (en) 2016-07-27
AU2010304091B2 (en) 2016-06-09
MX2012003782A (es) 2012-08-31
BR112012007828A2 (pt) 2016-03-08
MA33880B1 (fr) 2013-01-02

Similar Documents

Publication Publication Date Title
PE20121088A1 (es) Nuevos compuestos eficaces como inhibidores de la xantina-oxidasa, metodo para la preparacion de los mismos y composicion farmaceutica que los contiene
PE20140858A1 (es) Derivados de piperidina como inhibidores de renina
PE20130382A1 (es) Derivados de n-(imidazopirimidin-7-il)-heteroarilamida y su uso como inhibidores de pde10a
PE20080065A1 (es) Compuestos derivados de bencimidazol como moduladores del receptor vainilloide vr1
PE20130215A1 (es) Nuevos derivados de ciclohexilamina que tienen actividad como agonistas adrenergicos beta2 y como antagonistas muscarinicos m3
CR20110013A (es) Derivados de Heteroarilo como Inhibidores de DGAT1
CL2012001298A1 (es) Compuestos derivados del acido carbomoil-metilamino acetico sustituido, inhibidores de nep; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de hipertension arterial, hipertension pulmonar, insuficiencia cardiaca, entre otras.
BRPI0716069A2 (pt) composto, composiÇço farmacÊutica, e, mÉtodo para tratar um distérbio
CL2012002356A1 (es) Compuestos heterociclicos acidos derivados de ariltriazolonas ligadas a bisarilo, inhibidores de receptores de vasopresina v1a y v2; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar y/o prevenir insuficiencia cardiaca aguda y cronica, hiponatremia, entre otras.
AR074002A1 (es) Pirazolo e imidazopiridinilpirimidinaminas como inhibidores de la tirosina kinasa (igr-ir)
CR11803A (es) Pirrolopiridinas como inhibidores de cinasa
PE20120062A1 (es) Derivados de 1-bencil-2-amino-tetralina como inhibidores del transportador de glicina glyt1
PE20170914A1 (es) 1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3,2-d]pirimidin-4-onas como inhibidores de mieloperoxidasa
NO20082834L (no) 2-(fenyl eller heterosyklisk)-1H-fenantro[9,10-D]imidazoler som MPGES-1-inhibitorer
MX385616B (es) Inhibidores de cdk
PE20142364A1 (es) Compuestos para tratar atrofia muscular espinal
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
ECSP11011014A (es) Compuestos de pirazolopirimidina inhibidores de jak y métodos
PE20091565A1 (es) Derivados de 2-pirazinona como inhibidores de la elastasa de los neutrofilos
EA201290416A1 (ru) Новые спиропиперидиновые соединения
PE20091732A1 (es) Dihidropirazolonas sustituidas y su uso
EA201000007A1 (ru) Производные индазоламида
PE20090709A1 (es) Compuestos heterociclico de 5 miembros
PE20140934A1 (es) Derivados de pirazol
EA201200429A1 (ru) Производные циклопропиламида

Legal Events

Date Code Title Description
FG Grant, registration